NBE-002

N/A

Report date: 2024/02/05 14:07:58

Base Information

Drug NameNBE-002

Drug Alias NameNBE-002BI-3702025PNU-159682-anti-ROR1 antibody drug conjugate

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PNU-159682 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonistsWnt signalling pathway modulators

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsSolid tumoursTriple Negative Breast NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNbe-Therapeutics Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNbe-Therapeutics Ag

Active IndicationsN/A

Inactive IndicationsSolid tumoursTriple Negative Breast NeoplasmsNeoplasms

Other Information

ATC CodeN/A